Information Assurance and Security Ethics in Complex Systems: Interdisciplinary Perspectives

The risks associated with the misuse and abuse of genetic information are high, as the exploitation of an individual’s genetic information represents the ultimate example of identity theft. Hence, as the frontline of defense, information assurance and security (IAS) practitioners must be intimately familiar with the multidimensional aspects surrounding the use of genetic information in healthcare. To achieve that aim, this chapter addresses the ethical, privacy, economic, and legal aspects of the future uses of genetic information in healthcare and discusses the impact of these uses on IAS. The reader gains an effective ethical framework in which to understand and evaluate the competing demands placed upon the IAS practitioners by the transformative utility of genomics. DOI: 10.4018/978-1-61692-245-0.ch009

[1]  M. Pirmohamed,et al.  Warfarin Pharmacogenetics , 2012, PharmacoEconomics.

[2]  Janet Woodcock,et al.  Pharmacogenetics--tailoring treatment for the outliers. , 2009, The New England journal of medicine.

[3]  Wen Zhang,et al.  How much can behavioral targeting help online advertising? , 2009, WWW '09.

[4]  A. Buchanan,et al.  Pharmacogenomics: Ethical and Regulatory Issues , 2009 .

[5]  Adam Thierer,et al.  Online Advertising & User Privacy: Principles to Guide the Debate , 2008 .

[6]  Paul Ohm,et al.  The Rise and Fall of Invasive ISP Surveillance , 2008 .

[7]  A L Fuhlbrigge,et al.  Economic Evaluation of Pharmacogenetic Tests , 2008, Clinical pharmacology and therapeutics.

[8]  John A. Springer,et al.  Drug safety assurance through clinical genotyping: near-term considerations for a system-wide implementation of personalized medicine. , 2008, Personalized medicine.

[9]  Amy L McGuire,et al.  Confidentiality, privacy, and security of genetic and genomic test information in electronic health records: points to consider , 2008, Genetics in Medicine.

[10]  E. Layman,et al.  Ethical Issues and the Electronic Health Record , 2008, The health care manager.

[11]  Deni Elliott,et al.  Genetic Information Nondiscrimination Act , 2008 .

[12]  Daniel J. Solove.  Understanding Privacy (Chapter One) , 2008 .

[13]  P. Billings.  Beyond GINA , 2008, Nature Medicine.

[14]  D. Wysowski,et al.  Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. , 2007, Archives of internal medicine.

[15]  Diane M. Griffiths,et al.  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , 2007 .

[16]  Helen Nissenbaum,et al.  Privacy and contextual integrity: framework and applications , 2006, 2006 IEEE Symposium on Security and Privacy (S&P'06).

[17]  Craig R. Lee.  Warfarin initiation and the potential role of genomic-guided dosing. , 2005, Clinical medicine & research.

[18]  I. Björnsdottir,et al.  A lay prescription for tailor-made drugs--focus group reflections on pharmacogenomics. , 2005, Health policy.

[19]  Chris Jay Hoofnagle,et al.  Privacy Self Regulation: A Decade of Disappointment , 2005 .

[20]  Arthur N. Foxe M. D..  Oath of Hippocrates , 2005, Psychiatric Quarterly.

[21]  Herbert J. Mattord,et al.  Principles of Information Security , 2004 .

[22]  J. Craigie,et al.  The ethics of pharmacogenomics , 2004, Monash bioethics review.

[23]  H. Nissenbaum.  Privacy as contextual integrity , 2004 .

[24]  J. Harper.  Understanding Privacy—and the Real Threats to It , 2004 .

[25]  Jennifer L. Bevan,et al.  Informed lay preferences for delivery of racially varied pharmacogenomics , 2003, Genetics in Medicine.

[26]  Michael J Green,et al.  Genetic Exceptionalism in Medicine: Clarifying the Differences between Genetic and Nongenetic Tests , 2003, Annals of Internal Medicine.

[27]  K. Lindpaintner.  Pharmacogenetics and the future of medical practice , 2003, Journal of Molecular Medicine.

[28]  Matt Bishop,et al.  Computer Security: Art and Science , 2002 .

[29]  K. Lindpaintner.  Pharmacogenetics and the future of medical practice: conceptual considerations , 2001, The Pharmacogenomics Journal.

[30]  L. Kohn,et al.  To Err Is Human : Building a Safer Health System , 2007 .

[31]  A. Roses.  Pharmacogenetics and the practice of medicine , 2000, Nature.

[32]  T. Hollon.  NIH researchers receive cut-price BRCA test , 2000, Nature Medicine.

[33]  T. Brennan,et al.  Incidence and types of adverse events and negligent care in Utah and Colorado. , 2000, Medical care.

[34]  T. Hollon.  Researchers and regulators reflect on first gene therapy death , 2000, Nature Medicine.

[35]  Ethical issues in the use of genetic markers in occupational epidemiologic research. , 1999, Journal of occupational and environmental medicine.

[36]  A. Egberts,et al.  Adverse drug events in hospitalized patients A comparison of doctors, nurses and patients as sources of reports , 1999, European Journal of Clinical Pharmacology.

[37]  P. Davis.  Adverse drug events in hospitalized patients. , 1997, JAMA.

[38]  Paul F. Syverson,et al.  Anonymous connections and onion routing , 1997, Proceedings. 1997 IEEE Symposium on Security and Privacy (Cat. No.97CB36097).

[39]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[40]  C. Kozma,et al.  Genetic Discrimination: Perspectives of Consumers , 1996, Science.

[41]  Arthur Middleton Hughes.  The Complete Database Marketer: Second Generation Strategies and Techniques for Tapping the Power of Your Customer Database , 1995 .

[42]  J. Brodkey.  Neurosurgical Classics , 1993, Neurology.

[43]  R S Evans,et al.  Prevention of adverse drug events through computerized surveillance. , 1992, Proceedings. Symposium on Computer Applications in Medical Care.

[44]  Aristotle,et al.  THE NICOMACHEAN ETHICS , 1990 .

[45]  J. Rubenfeld.  The Right of Privacy , 1989 .

[46]  Jerome H. Saltzer,et al.  End-to-end arguments in system design , 1984, TOCS.

[47]  Jay Katz,et al.  The Silent World of Doctor and Patient , 1984 .

[48]  F. Schoeman,et al.  Philosophical Dimensions of Privacy , 1984 .

[49]  T. Beauchamp,et al.  Principles of biomedical ethics , 1991 .

[50]  A. Perl,et al.  Code of Ethics , 1879, The Independent practitioner.

[51]  Alice M. Tybout,et al.  Ethics in Marketing Research: Their Practical Relevance , 1974 .

[52]  Joseph Gray Jackson,et al.  Privacy and Freedom , 1968 .

[53]  A. B. Blankenship.  Some Aspects of Ethics in Marketing Research , 1964 .

[54]  R. Wilkins,et al.  NEUROSURGICAL CLASSIC. XVII. , 1964, Journal of neurosurgery.

[55]  Colston E. Warne.  Advertising—A Critic's View , 1962 .

[56]  Aristotle.  The Complete Works Of Aristotle , 1954 .

[57]  Louis D. Brandeis,et al.  The Right to Privacy , 1890 .